A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

Alcon

Status and phase

Completed

Phase 4

Conditions

Allergic Conjunctivitis

Treatments

Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

Study type

Interventional

Funder types

Industry

Identifiers

NCT01272089

C-11-013

Details and patient eligibility

About

The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study.

Enrollment

300 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

History (within the past 24 months) of allergic conjunctivitis.
Willing to avoid contact lens wear for each of the study visits, immediately prior to study medication installation and for 10 minutes after installation of study drug.
Contact lens wear should be stable and consistent for 3 months prior to Screening Visit (Day 1).
Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Contraindications or hypersensitivity to the use of the study medication or its components.
Inability or unwillingness to follow all study instructions and complete study visits as required.
Subjects with only one sighted eye or not correctable (using ETDRS chart) to 0.6 log MAR or better in both eyes at the Screening Visit.
A known history of recurrent corneal erosion syndrome (idiopathic or secondary to dry eye).
Ocular trauma within six months prior to Visit 1 in either eye as determined by subject history and/or examination.
Other protocol-defined exclusion criteria may apply.